Barry, OppHub America Desk · · Source: prnewswire-financial
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Of
Based on reporting from prnewswire-financial.
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules News provided by WallachBeth Capital LLC Aug 14, 2026, 11:45 ET Share this article Share to X Share this article Share to X JERSEY CITY, N.J. 14, 2026 /PRNewswire/ -- WallachBeth Capi
Market context for this story
As of: Regular HoursLoading quotes…
Informational only — not investment advice. Full markets →
$BIAF$BIAF
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/BIAF. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
fering Priced At-the-Market Under Nasdaq Rules News provided by WallachBeth Capital LLC Aug 14, 2026, 11:45 ET Share this article Share to X Share this article Share to X JERSEY CITY, N.J. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: $BIAF+WL ; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock. The combined effective offering price for each pre-funded warrant and accompanying two warrants to be issued is $0.4657.The pre-funded warrants will have an exercise price of $0.007 per share of common stock, and the warrants will have an initial exercise price of $0.4727 per share, will be exercisable following stockholder approval, and will expire five years from the date of issuance. The gross proceeds to the Company from the offering are estimated to be approximately $4.0 million before deducting the placement agent's fees and other estimated offering expenses.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story (crypto)
Coinbase
Gemini
Robinhood
Webull
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 14, 2026 at 11:57 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
biotech financing
A small medical testing company raised $4 million by selling new stock rights to investors. People who follow this company care because this cash helps them keep running their business, though it can also dilute the value of existing shares.
What changed
bioAffinity Technologies successfully closed a $4 million private placement offering.
Who wins / who loses
Micro-cap biotech investors and the company benefit from funding runway, while existing shareholders face dilution.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
low confidence · Active trader
Low confidence → prefer ETFs and “Watch,” not rushing into one stock.
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $BIAFWatch — track, don’t rush
The company raised money by selling new shares, which gives them cash to operate but means your piece of the pie represents a smaller percentage of the total company.
View $BIAF chart → · End-of-day delayed data
Second-order
- $XBIWatch — track, don’t rush
A basket of biotech stocks used to see how the overall small-cap medical sector is performing.
View $XBI chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should avoid options entirely here because small stocks can be unpredictable and trading options on them is very risky.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor upcoming SEC filings for insider participation in the private placement.
What would break this thesis
- Rapid cash burn exceeding the $4 million proceeds without clinical milestones.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-financial.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).